Commensal bacterial metabolites may strengthen the effect of anti-IL6 treatment for COVID-19
- 30 September 2021
- journal article
- letter
- Published by Elsevier BV in Clinical Immunology
- Vol. 232, 108870
- https://doi.org/10.1016/j.clim.2021.108870
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Butyrate Regulates COVID-19–Relevant Genes in Gut Epithelial Organoids From Normotensive RatsHypertension, 2021
- Altered gut microbial metabolites could mediate the effects of risk factors in Covid‐19Reviews in Medical Virology, 2021
- Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 PneumoniaJAMA Internal Medicine, 2021
- Effectiveness and safety of intravenous tocilizumab to treat COVID-19-associated hyperinflammatory syndrome: Covizumab-6 observational cohortClinical Immunology, 2020
- Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trialJournal of Translational Medicine, 2020
- IL-6 and CD8+ T cell counts combined are an early predictor of in-hospital mortality of patients with COVID-19JCI Insight, 2020
- The Role of Butyrate in Attenuating Pathobiont-Induced HyperinflammationImmune Network, 2020
- Bacterial butyrate prevents atherosclerosisNature Microbiology, 2018